Loss of UNC13A: how it exacerbates amyotrophic lateral sclerosis, and how to correct it

点击翻译按钮获取中文摘要

Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND), is a devastating neurodegenerative disorder that causes progressive loss of MNs, leading to impaired muscle function and paralysis. ALS is incurable and leads to death, usually caused by the inability to breathe, on average only 3 years after diagnosis, with a lifetime risk of about 1 in 400.A crucial player in the disease mechanism of ALS is a protein called TDP-43. TDP-43 mislocalisation in neurons occurs in ~97% of ALS, regardless of its many possible causes. TDP-43 is important for RNA splicing, a process by which RNA, the information deriving from DNA, is cut and re-assembled to provide cells with essential information. When TDP-43 cannot perform its function, numerous alterations of splicing occur, including a phenomenon called "cryptic exons", where novel random sequences are inserted into RNAs.In ALS brains, following TDP-43 alterations, multiple cryptic exon mistakes occur, and it has been difficult to understand which ones play a role in disease. We have now identified a novel cryptic exon event in the UNC13A gene. UNC13A encodes a protein that is important for the functioning of synapses, which allow neurons to transfer information between each other - the essential step for brain function.Unexpectedly, what makes the UNC13A cryptic exon different from the numerous other cryptic exons, is that genetics data from ALS patients supports it being very important for disease. In fact, a common genetic change in UNC13A has been long known to be associated with ALS, but why has remained elusive.Here, with the discovery of the UNC13A cryptic exon, we have been able to provide the missing link. In summary, when TDP-43 alterations occur in ALS, they induce the UNC13A cryptic exon, which in turn leads to a reduction of this crucial synaptic protein.Our hypothesis is that preventing this loss will have a positive impact on ALS disease course.In this research proposal we aim to better understand the UNC13A cryptic exon in ALS, its consequences and how we can prevent it from happening. We will:1. Identify in exactly what neuronal subtypes UNC13A is altered in ALS. This question is important to both understand the disease, and to know what we need to target in therapeutic interventions.We will answer our question by studying brains and spinal cords from ALS cases. We will visualise the altered UNC13A RNA and also use novel techniques that allow us to study all the RNAs in multiple single neurons from these cases.2. Investigate how the UNC13A cryptic exon impacts basic neuronal functions. This work will shed new light on disease mechanism in ALS and will be crucial to set up future assays for therapeutic development.We routinely use human (iPSC-derived) ALS cortical and motor neurons in culture and we can induce the UNC13A cryptic exon. We will study, with microscopy and electrophysiology, how the synapse functions in these neurons, and we will also study if other neuronal problems associated with ALS are impacted by the UNC13A cryptic exon.3. Understand the mechanism underlying the UNC13A cryptic exon and devise strategies to prevent it. This will allow us to understand how the UNC13A cryptic exon occurs, and will allow us to design oligonucleotide strategies - currently being used in the clinic for other neurological diseases - to interfere with this toxic mechanism. We have developed small versions of UNC13A that allow us to study the splicing mechanism very effectively. We will use this system also to efficiently screen and identify the best oligonucleotides for preventing this event.In summary, this project will contribute to understanding how changes in UNC13A, induced by TDP-43, impact on neurons and ALS pathogenesis, regardless of underlying cause. Crucially, this project will also develop an approach to prevent these changes and perform the initial steps for a potential therapeutic strategy for ALS.